Tag:
Xeloda
Latest Headlines
Latest Headlines
Top 10 Best-selling Cancer Drugs in 2011
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
NICE opens door to Roche, AZ cancer drugs
The U.K.'s cost-effectiveness watchdog has given the final nod to a trio of cancer drugs--Roche's Xeloda and MabThera, and AstraZeneca's Iressa--which means the NHS must provide funding and resources
ALSO NOTED: FDA: New Zyprexa sedates some;Vanderbilt outlaws rep freebies;
> Prepping for advisory panel review, FDA staff says long-lasting Zyprexa causes drowsiness. Report > Vanderbilt Medical
BMS cancer med could earn $500M
Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as
Press Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOX
Press Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOX
ALSO NOTED: NitroMed names new CEO; Drug cuts tumors' metabolic rate; and much more...
> Chutes & Ladders : NitroMed has named Kenneth Bate as its new CEO. Release
> Researchers say that updated data from an early-stage trial shows that IPI-504--being developed by Infinity Pharmaceuticals and Medimmune--cut the metabolic rate of tumors. Report
> The FDA has granted Chelsea Therapeutics orphan drug …
ALSO NOTED: Celgene buys plant; Roche data positive on Xeloda; Merck, Vertex to advance MK-0457; and much more...
> Celgene is buying an active ingredient plant from Switzerland's Siegfried for $46.5 million. Report
> Roche announced that its latest Phase III trial for Xeloda hit its primary endpoint in a study on progression-free cancer survival. Release
> Merck and Vertex announced that MK-0457 will move into Phase II for leukemia after successfully …
Press Release: Xeloda Combination Meets Primary Endpoint in Phase III Study
Press Release: Xeloda Combination Meets Primary Endpoint in Phase III Study
ALSO NOTED: Europe expands Synvisc approval; FDA issues "approvable" letter for paliperidone; and much more...
> European regulators have agreed to expand the approval of Genzyme's Synvisc to include osteoarthritis of the ankle and shoulder. Report
> J&J says its subsidiary has received an approvable letter from the FDA for paliperidone as a therapy for schizophrenia. But the drug maker did not say what issues were still left to be resolved. …
ALSO NOTED: Serono inks pact with Syntonix; Sanofi mentioned as possible BMS suitor; and much more...
> Serono has signed a development and commercialization pact with Syntonix Pharmaceuticals for its FSH:Fc candidates to treat infertility. Syntonix gains a collaboration fee and will stand to earn up to $54 million in milestones if Serono exercises its option in the deal. Report
> You can add the name of Sanofi-Aventis to the growing list of potential suitors for Bristol-Myers Squibb. …
